^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD70-targeted CAR-T immunotherapy

    Related drugs:
    2ms
    CD19/70 Bi-specific CAR-T Cell Therapy (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Jun 2026 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    2ms
    GD2/CD70 Bi-specific CAR-T Cell Therapy (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Jun 2026 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    CD70 (CD70 Molecule)
    2ms
    PSMA/CD70 Bi-specific CAR-T Cell Therapy (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Jun 2026 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    CD70 (CD70 Molecule)
    2ms
    Multi-CAR-T Cells Targeting B Cell Lymphomas (clinicaltrials.gov)
    P1/2, N=11, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 --> Dec 2030 | Trial primary completion date: Jul 2023 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule) • CD79B (CD79b Molecule) • CD22 (CD22 Molecule) • CD70 (CD70 Molecule) • ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    multi-CAR-T cell therapy
    2ms
    The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=30, Recruiting, Chinese PLA General Hospital
    New P1 trial
    |
    CD70 (CD70 Molecule)
    2ms
    IMPACT: IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma (clinicaltrials.gov)
    P1, N=39, Recruiting, University of Florida | Active, not recruiting --> Recruiting
    Enrollment open
    |
    CD70 (CD70 Molecule)
    |
    8R-70CAR T
    3ms
    IMPACT: IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG) (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, University of Florida | N=18 --> 24
    Enrollment change
    |
    8R-70CAR T
    3ms
    IMPACT MET: IL-8 Receptor Modified Patient-Derived Activated CD70 CAR T Cell Therapy in Adults With Brain Metastases (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, University of Florida
    New P1 trial
    |
    8R-70CAR T
    4ms
    Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=15, Recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Trial primary completion date: Feb 2026 --> Mar 2027
    Trial primary completion date
    4ms
    A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=12, Completed, CRISPR Therapeutics | Recruiting --> Completed | N=290 --> 12 | Trial completion date: Nov 2030 --> Mar 2026 | Trial primary completion date: May 2030 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CTX131
    4ms
    A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors（CROWN） (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P1 trial
    5ms
    CRISPR-Mediated Cancer Therapies: Approaches to Direct Tumor Targeting. (PubMed, Crit Rev Oncol Hematol)
    Clinical trials with CRISPR-engineered T-cells (e.g., CTX130) have demonstrated remission rates in hematologic malignancies. However, significant challenges remain, including cytokine release syndrome, immunotoxicity, tumor heterogeneity, and limited delivery efficiency in solid tumors. Overcoming these barriers requires interdisciplinary innovation, ethical oversight, and technological refinement to support the safe and effective integration of CRISPR-based strategies into precision oncology.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    KRAS G12D • KRAS G12
    |
    CTX130